Isopentyl caffeate as a promising drug for the treatment of leishmaniasis : An in silico and in vivo study

Thumbnail Image
1-s2.0-S2590262824000352-main.pdf (6.54 MB)
Identifiers
URI: https://hdl.handle.net/10641/7839
ISSN: 2590-2628
DOI: 10.1016/j.crbiot.2024.100209

Publication date

2024-01

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Doctoral program

Description

Publisher Copyright: © 2024 The Author(s)

Keywords

ADME, Bioavailability, In silico, Isopentyl caffeate, Leishmania, Pharmacokinetics, Biotechnology, SDG 3 - Good Health and Well-being, Yes, yes

Citation

Mota, W S, Oliveira, S S C, Pereira, M M, Souza, D P, Castro, M, Gomes, P S, Guedes, H L M, Souza, V F, Santos, A L S, Albuquerque-Junior, R L C, Cardoso, J C, Blanco-Llamero, C, Jain, S, Souto, E B & Severino, P 2024, 'Isopentyl caffeate as a promising drug for the treatment of leishmaniasis : An in silico and in vivo study', Current Research in Biotechnology, vol. 7, 100209. https://doi.org/10.1016/j.crbiot.2024.100209

Collections

FACULTAD DE CIENCIAS DE LA SALUD